At a glance
ClinicalIndex Comparison RecordPhase 2Active· 200 target
Drug / intervention
MHB036Cdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
NCT06373406Phase 2ActiveUpdate OverdueUpdated 7mo ago · Completion was 6mo agoEnrollment Stalled
A Phase I/II, Dose Escalation and Dose Expansion Study of MHB036C for Advanced Solid Tumor to Evaluate the Tolerability/Safety, Pharmacokinetics and Efficacy
In Brief
A Phase 2 clinical trial evaluating MHB036C for Advanced Solid Tumor. Active but no longer recruiting, targeting 200 participants across 1 site.
Signals
Enrollment appears stalled
Detailed Summary
Phase I/II, dose escalation and dose expansion study to evaluate the efficacy and safety of MHB036C in advanced malignant tumors.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Solid Tumor
CountriesChina
Collaborators--
Timeline
Phase 2Active
2024202520262027
Enrollment StartMay 2023
First PostedApr 2024
Primary CompletionDec 2025
TodayJul 2026
Study CompletionDec 2026
First PostedApr 18, 2024
Enrollment StartMay 26, 2023
Primary CompletionDec 1, 2025
Study CompletionDec 1, 2026
TodayJul 1, 2026
Enrollment to primary: 2.5 yearsPosted 2.2 years ago
Interventions
MHB036Cdrug
An antibody-drug conjugate therapy